|
Market Closed -
Nasdaq
21:00:00 28/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.960 USD | +3.16% |
|
-12.89% | -77.85% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 19.56 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -74.34% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 19.56 | 19.56 | 19.56 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -74.34% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.51x | -0.62x | 0.72x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | 0.1x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.16x |
| EV / Revenue | - | - | - | - | - | - | - | 0.16x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.55x | -0.51x | 0.4x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -3.84 | -3.143 | 2.715 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -35.88 | -38.03 | 49.46 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -34.89 | -38.03 | 49.46 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 1.960 | 1.960 | 1.960 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 9,979 | - | - |
| Announcement Date | 28/02/22 | 22/03/23 | 01/04/24 | 25/03/25 | 25/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.49x | - | - | - | 18.96M | |
| 33.26x | 5.97x | 17.88x | 0.98% | 47.97B | |
| 34.82x | 3.35x | 14.46x | -.--% | 44.5B | |
| -21.07x | 227.64x | -22.77x | -.--% | 43.93B | |
| 47.27x | 5.47x | 29.96x | -.--% | 41.03B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.85B | |
| 35.19x | 5.78x | 26.24x | -.--% | 17.27B | |
| -61.04x | 9.99x | 243.78x | -.--% | 15.34B | |
| 25.79x | 2.21x | 9.6x | 1.04% | 15.3B | |
| Average | 13.40x | 33.52x | 42.38x | 0.3% | 28.36B | |
| Weighted average by Cap. | 19.70x | 43.80x | 26.11x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
